TrimTabs Asset Management LLC lessened its holdings in Zoetis Inc. (NYSE:ZTS) by 49.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,354 shares of the company’s stock after selling 7,065 shares during the period. TrimTabs Asset Management LLC’s holdings in Zoetis were worth $1,148,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors have also made changes to their positions in the stock. BlackRock Inc. increased its stake in shares of Zoetis by 3.3% in the 4th quarter. BlackRock Inc. now owns 40,720,915 shares of the company’s stock valued at $6,739,311,000 after purchasing an additional 1,291,599 shares in the last quarter. Alliancebernstein L.P. increased its stake in shares of Zoetis by 9.1% in the 4th quarter. Alliancebernstein L.P. now owns 16,645,263 shares of the company’s stock valued at $2,754,791,000 after purchasing an additional 1,386,823 shares in the last quarter. FMR LLC increased its stake in shares of Zoetis by 27.4% in the 4th quarter. FMR LLC now owns 14,036,704 shares of the company’s stock valued at $2,323,075,000 after purchasing an additional 3,017,046 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in Zoetis by 0.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 9,149,759 shares of the company’s stock worth $1,514,285,000 after buying an additional 29,465 shares in the last quarter. Finally, Norges Bank purchased a new stake in Zoetis during the 4th quarter worth approximately $763,474,000. Hedge funds and other institutional investors own 92.50% of the company’s stock.
Several equities research analysts have commented on ZTS shares. Raymond James upgraded Zoetis from a “market perform” rating to an “outperform” rating and set a $166.00 price objective for the company in a research note on Monday, March 15th. Credit Suisse Group boosted their price objective on Zoetis from $197.00 to $203.00 in a research note on Wednesday, February 17th. Finally, Bank of America upgraded Zoetis from a “neutral” rating to a “buy” rating and set a $180.00 price objective for the company in a research note on Monday, March 15th. Six research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Zoetis has a consensus rating of “Buy” and a consensus price target of $170.08.
Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, February 16th. The company reported $0.91 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.86 by $0.05. The business had revenue of $1.81 billion for the quarter, compared to analysts’ expectations of $1.73 billion. Zoetis had a return on equity of 63.89% and a net margin of 25.50%. During the same period in the previous year, the firm posted $0.92 EPS. Research analysts forecast that Zoetis Inc. will post 3.63 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 1st. Investors of record on Wednesday, April 21st will be issued a $0.25 dividend. This represents a $1.00 dividend on an annualized basis and a yield of 0.62%. The ex-dividend date of this dividend is Tuesday, April 20th. Zoetis’s dividend payout ratio is presently 27.47%.
In other Zoetis news, Director Robert W. Scully acquired 7,590 shares of the firm’s stock in a transaction that occurred on Friday, February 19th. The shares were purchased at an average cost of $164.68 per share, for a total transaction of $1,249,921.20. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Robert Edward Kelly sold 2,054 shares of the company’s stock in a transaction that occurred on Thursday, February 11th. The shares were sold at an average price of $161.15, for a total value of $331,002.10. Following the completion of the transaction, the executive vice president now owns 10,029 shares in the company, valued at $1,616,173.35. The disclosure for this sale can be found here. Corporate insiders own 0.17% of the company’s stock.
Zoetis Company Profile
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Read More: Quiet Period
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.